Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced that it has entered into a research cooperation agreement with Suzhou Ditu Zhiyuan Biotechnology Co., Ltd. (“Ditu Zhiyuan“) to conduct translational and clinical medical research centered on Hanx’s proprietary innovative oncology drug pipeline, leveraging Ditu Zhiyuan’s independently developed Meritudio BioAI cloud platform. The collaboration integrates artificial intelligence, multi‑omics bioinformatics, and clinical medical big data analytics to support study design and clinical development strategy.
Collaboration Snapshot
| Item | Detail |
|---|---|
| Parties | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) and Suzhou Ditu Zhiyuan Biotechnology Co., Ltd. |
| Agreement Type | Research cooperation agreement (non‑exclusive scope not disclosed) |
| Platform | Meritudio BioAI cloud platform, independently developed by Ditu Zhiyuan |
| Focus | Translational and clinical medical research on Hanx’s proprietary innovative oncology pipeline |
| Technology Stack | Artificial intelligence, multi‑omics bioinformatics, clinical medical big data analysis |
| Deliverables | Big data support and AI technology guidance for preclinical/translational research plans and clinical development strategies |
| Announcement Date | 16 Nov 2026 |
| Financial Terms | Not disclosed |
Platform Profile & Technical Scope
- Core Platform: Meritudio BioAI, a cloud‑based AI research environment developed in‑house by Ditu Zhiyuan for biopharmaceutical R&D applications.
- Multi‑Omics Integration: Bioinformatics analysis spanning genomic, transcriptomic, and proteomic datasets to inform target biology and biomarker hypotheses.
- Clinical Big Data: Analysis of clinical medical datasets intended to support patient selection, endpoint design, and development strategy.
- Application Layer: AI‑assisted formulation of preclinical and translational research plans and clinical development strategies for Hanx’s innovative drug candidates.
- Program‑Level Detail: Specific pipeline assets, indications, and study timelines under the collaboration were not disclosed.
Partner Profiles
- Hanx Biopharmaceuticals: Established in 2014; an innovative biotechnology company dedicated to structural biology, translational medicine, and clinical development, with a stated commitment to developing next‑generation immunotherapies. Listed on the Hong Kong Stock Exchange under ticker 3378.
- Ditu Zhiyuan: An R&D service and software enterprise serving the biopharmaceutical industry, providing professional services in artificial intelligence, bioinformatics, statistics, and data science, together with supporting software development.
Market Impact & Outlook
- AI‑Enabled Oncology R&D: Computational infrastructure applied to translational design is increasingly central to oncology programs, where biomarker‑driven patient selection materially influences trial efficiency and success rates.
- Pipeline Differentiation: For a company positioned around structural biology and next‑generation immunotherapies, embedding multi‑omics and clinical big data into study design supports mechanism‑driven candidate prioritization.
- Capital‑Light Build vs. Buy: Partnering with an external AI/bioinformatics vendor allows Hanx to access modeling and data science capability without disclosed upfront platform investment, a common structure in China’s biotech AI services market.
- Services Demand Signal: The agreement reflects continued demand for AI‑plus‑bioinformatics service providers in China’s pharmaceutical R&D ecosystem, where platform vendors are being engaged directly at the translational stage rather than solely in early discovery.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the scope, progress, and outcomes of the research cooperation between Hanx Biopharmaceuticals and Ditu Zhiyuan, including the application of the Meritudio BioAI platform to preclinical, translational, and clinical development activities. Actual results may differ due to risks including research feasibility, data availability and quality, regulatory requirements, clinical trial outcomes, and the parties’ ability to execute the agreement. No financial terms, milestones, or specific pipeline timelines have been disclosed.-Fineline Info & Tech
